Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Xenon Pharmaceuticals Inc (XENE)

292 + Investors. Track Smart Money conviction in XENE. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +42
Streak
3Q ▲
Buyers last Q
67%

Smart Money Signals — XENE

Based on 294 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 3 quarters in a row

last 6Q
For 3 consecutive quarters, more hedge funds added XENE than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🏔️

At the ownership peak (100% of max)

100% of all-time peak
294 hedge funds hold XENE right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
🚀

Fast accumulation — +41% more funds vs a year ago

fund count last 6Q
+85 new funds entered over the past year (+41% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.
🟢

More buyers than sellers — 67% buying

207 buying100 selling
Last quarter: 207 funds were net buyers (79 opened a brand new position + 128 added to an existing one). Only 100 were sellers (63 trimmed + 37 sold completely). A clear majority buying is a strong confirmation signal.
📈

More new buyers each quarter (+22 vs last Q)

new funds entering per quarter
Funds opening a new XENE position: 40 → 35 → 57 → 79. A growing influx of new institutional buyers means the asset is still gathering momentum — the consensus hasn't fully saturated yet.
🔒

50% of holders stayed for 2+ years

■ 50% conviction (2yr+) ■ 19% medium ■ 31% new
147 out of 294 hedge funds have held XENE for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
💰

Value +51% but shares only +20% — price-driven

Value
+50%
Shares
+19%
Last quarter: the total dollar value of institutional holdings rose +51%, but actual share count only changed +20%. The gap is explained by the stock's price rising — not new buying. Strong value growth with weak share growth means the rally is price momentum, not fresh institutional demand.
🚀

Acceleration phase — new buyers rushing in

21 → 40 → 35 → 57 → 79 new funds/Q
New funds entering each quarter: 40 → 35 → 57 → 79. The pace of institutional discovery is accelerating sharply. This is the 'hot idea' phase — the thesis is being passed from fund to fund. You are not late — the accumulation wave is still building.
🏛️

Deep conviction — 58% of holders stayed 2+ years

■ 58% veterans ■ 9% 1-2yr ■ 33% new
Of 306 current holders: 178 (58%) have held for over 2 years without selling. These are not momentum buyers — they have lived through drawdowns and stayed. A large veteran base acts as a stabilizing force during selloffs.
🏆

Elite ownership — 41% AUM from top-100 funds

41% from top-100 AUM funds
53 of 294 holders are among the 100 largest funds by AUM, controlling 41% of total institutional value in XENE. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.
4.4
out of 10
Moderate Exit Risk
Exit risk score 4.4/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — XENE

In 2026 Q1, 207 hedge funds were net buyers of XENE (79 opened a new position, 128 added to an existing one), while 100 reduced or exited (63 trimmed, 37 sold completely) — a 67% buyer ratio, indicating clear institutional accumulation. This marks 3 consecutive quarters of net institutional buying — a persistent conviction signal. 41% of total institutional value in XENE is held by top-100 AUM funds, reflecting elite-tier ownership quality. Net fund flow last quarter: +42 funds (more new holders than closures). Total institutional holders: 294.

Hedge Fund Ownership: XENE

How many hedge funds hold XENE — quarterly history vs. share price
Quarterly hedge fund ownership of XENE vs. share price

Market Analysis: XENE

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: XENE

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Xenon Pharmaceuticals Inc (XENE) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much XENE has moved relative to its sector benchmark (XLV) since the 2026 Q1 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End March 31, 2026 · 81d ago
XENE
nan%
XLV
+2.1%

XENE outperformed XLV by nan% since March 31, 2026.

Since 13F Filing Date May 15, 2026 · 36d ago
XENE
nan%
XLV
+3.2%

Since the filing became public, XENE outperformed XLV by nan% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

28 top-rated funds 7 high-conviction
Consensus
6.3
/ 10
breadth
×
Elite
5.3
/ 10
conviction
Hedge Fund Positioning: XENE
292 + Investors

Track Smart Money conviction in XENE. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 292 252 15.87%
13F Shares 103M 86M 19.53%
Total Value $5.74B $3.80B 50.93%
New Positions 77 57 +20
Increased Positions 130 81 +49
Closed Positions 37 24 +13
Reduced Positions 57 74 -17
Total Calls 9 7 28.57%
Total Puts 7 8 -12.5%
PUT/CALL Ratio 0.78 1.14 Neutral

Statistics: XENE

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

292 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in XENE. Verified SEC 13F-HR filings.

QUARTER:
Top 25 XENE holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Trails Edge Capital Partners, LP 5.86% 440,000 $25.6M
2 Caligan Partners LP 5.39% 1,393,027 $81.0M
3 First Turn Management, LLC 5.11% 786,844 $45.8M
4 Affinity Asset Advisors, LLC 5.03% 1,675,000 $97.4M
5 NEXTBio Capital Management LP 4.95% 183,225 $10.7M
6 Foresite Capital Management IV, LLC 3.92% 160,000 $9.3M
7 DAFNA Capital Management LLC 3.32% 250,772 $14.6M
8 Avoro Capital Advisors LLC 3.31% 5,777,777 $336.0M
9 Octagon Capital Advisors LP 3.15% 490,000 $28.5M
10 Parkman Healthcare Partners LLC 2.98% 497,035 $28.9M
11 Commodore Capital LP 2.78% 825,000 $48.0M
12 Trails Edge Capital Partners, LP 2.66% 200,000 $11.6M
13 MPM BioImpact LLC 2.64% 588,706 $34.2M
14 Rock Springs Capital Management LP 2.62% 763,020 $44.4M
15 Braidwell LP 2.60% 1,338,452 $77.8M
16 Patient Square Capital LP 2.34% 227,000 $13.2M
17 Novo Holdings A/S 2.29% 485,438 $28.2M
18 Siren, L.L.C. 2.13% 1,318,564 $76.7M
19 Driehaus Capital Management LLC 1.92% 4,491,653 $261.2M
20 Stempoint Capital LP 1.59% 140,755 $8.2M
21 NAN FUNG TRINITY (HK) Ltd 1.58% 247,765 $14.4M
22 Act Capital Management, LLC 1.53% 33,500 $1.9M
23 Logos Global Management LP 1.31% 450,000 $26.2M
24 Orbimed Advisors LLC 1.22% 1,059,971 $61.6M
25 Silverarc Capital Management, LLC 1.17% 197,759 $11.5M
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Xenon Pharmaceuticals Inc (XENE)

What does the Smart Money Trend signal show for XENE?

Buying streak — 3 quarters in a row: For 3 consecutive quarters, more hedge funds added XENE than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for XENE?

More buyers than sellers — 67% buying: Last quarter: 207 funds were net buyers (79 opened a brand new position + 128 added to an existing one). Only 100 were sellers (63 trimmed + 37 sold completely). A clear majority buying is a strong confirmation signal.

What is the fund quality score for XENE holders?

Elite ownership — 41% AUM from top-100 funds: 53 of 294 holders are among the 100 largest funds by AUM, controlling 41% of total institutional value in XENE. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

How long have hedge funds held XENE?

50% of holders stayed for 2+ years: 147 out of 294 hedge funds have held XENE for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Xenon Pharmaceuticals Inc (XENE) following the 2026 Q1 hedge fund 13F filings?

As of today, XENE has moved nan% since the 2026 Q1 13F filing date (May 15, 2026), compared to +3.2% for the XLV sector ETF — an outperformance of nan%. Since the quarter end (March 31, 2026), XENE has gained nan% vs +2.1% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →